BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38238453)

  • 1. The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.
    Salafian K; Mazimba C; Volodin L; Varadarajan I; Pilehvari A; You W; Knio ZO; Ballen K
    Bone Marrow Transplant; 2024 Apr; 59(4):459-465. PubMed ID: 38238453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia.
    Liam CCK; Boo YL; Lee YL; Law KB; Ho KW; Shahnaz SAKS; Tan JTC; Lau NS; Ong TC; Tan SM; Sathar J
    Blood Cell Ther; 2021 Feb; 4(1):1-8. PubMed ID: 36712843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of social vulnerability subthemes on postoperative outcomes differs by racial/ethnic minority status.
    Diaz A; Hyer JM; Tsilimigras D; Pawlik TM
    Am J Surg; 2022 Feb; 223(2):353-359. PubMed ID: 34099239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
    Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN
    JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
    Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
    Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
    Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
    Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
    Mikulski D; Kościelny K; Nowicki M; Wawrzyniak E; Kalwas M; Kowalik M; Pryt M; Sęczkowska E; Świątek A; Wierzbowska A; Fendler W
    Leuk Lymphoma; 2023 Jan; 64(1):98-106. PubMed ID: 36318865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
    Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
    Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
    Suzuki K; Shimazu Y; Minakata D; Ikeda T; Takahashi H; Tsukada N; Kanda Y; Doki N; Nishiwaki K; Miwa A; Sawa M; Kataoka K; Hiramoto N; Ota S; Itagaki M; Ichinohe T; Atsuta Y; Yano S; Kawamura K;
    Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
    Geng C; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Yang G; Chen W
    BMC Cancer; 2022 Dec; 22(1):1349. PubMed ID: 36564753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
    Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
    Lemieux C; Muffly LS; Rezvani A; Lowsky R; Iberri DJ; Craig JK; Frank MJ; Johnston LJ; Liedtke M; Negrin R; Weng WK; Meyer E; Shizuru J; Shiraz P; Arai S; Miklos DB; Sidana S
    Bone Marrow Transplant; 2021 Feb; 56(2):368-375. PubMed ID: 32782351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.